Altimmune (ALT) Preferred Stock Liabilities (2017 - 2018)
Altimmune (ALT) posted quarterly Preferred Stock Liabilities of $917.0 for Q3 2018, down 99.99% year-over-year from $8.2 million in Q3 2017, and down 99.51% quarter-over-quarter from $186685.0 in Q2 2018.
Powered by 
Analysis
Altimmune (ALT) Preferred Stock Liabilities (2017 - 2018) Analysis & Trends
Altimmune (ALT) has reported Preferred Stock Liabilities for 2 consecutive years, with $917.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Preferred Stock Liabilities fell 99.99% year-over-year to $917.0; the TTM figure through Sep 2018 stood at $917.0 (down 99.99% YoY), while the FY2017 annual figure was $27236.0, changed N/A from the prior year.
- Preferred Stock Liabilities retreated to $917.0 in Q3 2018 per ALT's latest filing, from $186685.0 in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $8.2 million in Q3 2017 and bottomed at $917.0 in Q3 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Altimmune | 636.07 Mn | 636.07 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2018 | 917.00 |
| Jun 30, 2018 | 186,685.00 |
| Mar 31, 2018 | 34,278.00 |
| Dec 31, 2017 | 27,236.00 |
| Sep 30, 2017 | 8.24 Mn |